An update on emerging drugs in osteosarcoma: towards tailored therapies?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An update on emerging drugs in osteosarcoma: towards tailored therapies?
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume -, Issue -, Pages 1-19
Publisher
Informa UK Limited
Online
2019-08-12
DOI
10.1080/14728214.2019.1654455
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models
- (2019) Maria Carolina Ruiz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Larotrectinib: First Global Approval
- (2019) Lesley J. Scott DRUGS
- Therapeutic Targets for Bone and Soft-Tissue Sarcomas
- (2019) Shinji Miwa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment
- (2019) Claudia Maria Hattinger et al. Expert Opinion on Drug Metabolism & Toxicology
- Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
- (2019) Sigbjørn Smeland et al. EUROPEAN JOURNAL OF CANCER
- Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma
- (2019) Lijun Cheng et al. BMC Medical Genomics
- CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
- (2019) Benedetto Sacchetti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
- (2019) Marilina García-Aranda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
- (2019) Charlie Gourley et al. JOURNAL OF CLINICAL ONCOLOGY
- Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
- (2019) Fiona M. Behan et al. NATURE
- Targeting ERK1/2 protein-serine/threonine kinases in human cancers
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment
- (2019) Monica Capozzi et al. Cancer Management and Research
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
- (2019) Lara E. Davis et al. JOURNAL OF CLINICAL ONCOLOGY
- Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts
- (2019) Elena Gazzano et al. CANCER LETTERS
- Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3
- (2018) Bingxin Zheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
- (2018) Yubing Zhou et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
- (2018) Lu Xie et al. BMC CANCER
- Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study
- (2018) Baorang Zhu et al. CANCER BIOLOGY & THERAPY
- Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines
- (2018) Maria Ferraiuolo et al. CANCER LETTERS
- Hydroxychloroquine: An old drug with new relevance
- (2018) E. A. SHIPPEY et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Phase I results of a phase I/II study of weekly nab -paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
- (2018) Lucas Moreno et al. EUROPEAN JOURNAL OF CANCER
- A Potential Bone-Targeting Hypotoxic Platinum(II) Complex with an Unusual Cytostatic Mechanism toward Osteosarcoma Cells
- (2018) Zhenqin Zhang et al. INORGANIC CHEMISTRY
- Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
- (2018) Sarina Gouravan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
- (2018) Hye Jeong Park et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The landscape of genomic alterations across childhood cancers
- (2018) Susanne N. Gröbner et al. NATURE
- Immunotherapy for osteosarcoma: Where do we go from here?
- (2018) Mary F. Wedekind et al. PEDIATRIC BLOOD & CANCER
- Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy
- (2018) Bushra Weidenbusch et al. Oncotarget
- Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
- (2018) M. Fioramonti et al. Scientific Reports
- Understanding osteosarcomas
- (2018) Emily Simpson et al. JAAPA-Journal of the American Academy of Physician Assistants
- The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas
- (2018) Steven G. DuBois et al. CANCER
- Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases
- (2018) Kai Zheng et al. MEDICINE
- Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
- (2018) Xiaotu Ma et al. NATURE
- Lenvatinib
- (2018) Koichi Suyama et al. Cancer Control
- Identification of Novel Target for Osteosarcoma by Network Analysis
- (2018) Li-Qiang Zhi et al. MEDICAL SCIENCE MONITOR
- Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma
- (2018) Ilaria Buondonno et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?
- (2018) Claudia Maria Hattinger et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma
- (2018) Elisa Martella et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Florence Duffaud et al. LANCET ONCOLOGY
- Phase-II trials in osteosarcoma recurrences: A systematic review of past experience
- (2017) Natacha Omer et al. EUROPEAN JOURNAL OF CANCER
- Novel insights and therapeutic interventions for pediatric osteosarcoma
- (2017) Leo Kager et al. Future Oncology
- Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis
- (2017) Mohammad Mashreghi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
- (2017) Ymera Pignochino et al. Molecular Cancer
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
- (2017) Timothy P.S. Perera et al. MOLECULAR CANCER THERAPEUTICS
- Exploring targeted therapy of osteosarcoma using proteomics data
- (2017) Parunya Chaiyawat et al. OncoTargets and Therapy
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy
- (2017) Janice M. Santiago-O’Farrill et al. Oncotarget
- Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma
- (2016) Marilù Fanelli et al. CURRENT CANCER DRUG TARGETS
- The role of pharmacogenetics in the treatment of osteosarcoma
- (2016) Hanneke I. Vos et al. DRUG DISCOVERY TODAY
- Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study
- (2016) Barbara C. Worst et al. EUROPEAN JOURNAL OF CANCER
- MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer
- (2016) Julia Carnevale et al. Future Oncology
- Progress and opportunities for immune therapeutics in osteosarcoma
- (2016) Christina K Lettieri et al. Immunotherapy
- Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial
- (2016) Sophie Piperno-Neumann et al. LANCET ONCOLOGY
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
- (2016) Neyssa M Marina et al. LANCET ONCOLOGY
- Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients
- (2016) Claudia M Hattinger et al. PHARMACOGENOMICS
- The pharmacogenomics of osteosarcoma
- (2016) M Serra et al. PHARMACOGENOMICS JOURNAL
- Therapeutics Targeting FGF Signaling Network in Human Diseases
- (2016) Masaru Katoh TRENDS IN PHARMACOLOGICAL SCIENCES
- Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
- (2016) Florian Engert et al. Oncotarget
- Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
- (2015) Yolanda González-Fernández et al. CURRENT PHARMACEUTICAL DESIGN
- Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?
- (2015) Leo Kager et al. Expert Opinion on Drug Metabolism & Toxicology
- Advances in emerging drugs for osteosarcoma
- (2015) Claudia Maria Hattinger et al. EXPERT OPINION ON EMERGING DRUGS
- An update on chemotherapy for osteosarcoma
- (2015) Stefano Ferrari et al. EXPERT OPINION ON PHARMACOTHERAPY
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
- (2015) Stefan S. Bielack et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
- (2015) Michael S. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis
- (2015) Branden S Moriarity et al. NATURE GENETICS
- Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
- (2015) Michael Roth et al. PEDIATRIC BLOOD & CANCER
- Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)
- (2015) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
- Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
- (2015) Amy B. Hall et al. Oncotarget
- Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
- (2014) Akmal Safwat et al. ACTA ONCOLOGICA
- Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
- (2014) B. Kasper et al. ANNALS OF ONCOLOGY
- Effects of Nanosized Lithium Carbonate Particles on Intact Muscle Tissue and Tumor Growth
- (2014) N. P. Bgatova et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Multiple relapses in high-grade osteosarcoma: When to stop aggressive therapy?
- (2014) Gevorg Tamamyan et al. PEDIATRIC BLOOD & CANCER
- The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma
- (2014) Xin Xiao et al. PEDIATRIC DRUGS
- Targeting the DNA Repair Pathway in Ewing Sarcoma
- (2014) Elizabeth Stewart et al. Cell Reports
- Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma
- (2013) Michael Roth et al. CANCER
- The emerging role of MET/HGF inhibitors in oncology
- (2013) Giorgio V. Scagliotti et al. CANCER TREATMENT REVIEWS
- Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
- (2013) L. Zhang et al. CLINICAL CANCER RESEARCH
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
- (2013) Gary K Schwartz et al. LANCET ONCOLOGY
- Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
- (2013) Gemma Gatta et al. LANCET ONCOLOGY
- Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
- (2013) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- The Efficacy of Abraxane on Osteosarcoma Xenografts in Nude Mice and Expression of Secreted Protein, Acidic and Rich in Cysteine
- (2012) Yongkun Yang et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
- (2011) Hilary Glen et al. BMC CANCER
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
- (2011) Jakob K. Anninga et al. EUROPEAN JOURNAL OF CANCER
- Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
- (2011) Hans Gelderblom et al. EUROPEAN JOURNAL OF CANCER
- Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
- (2011) Skjalg Bruheim et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting microRNAs in cancer: rationale, strategies and challenges
- (2010) Ramiro Garzon et al. NATURE REVIEWS DRUG DISCOVERY
- Review of mifamurtide in the treatment of patients with osteosarcoma
- (2010) Leo Kager et al. Therapeutics and Clinical Risk Management
- Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients
- (2009) Berger Massimo et al. CANCER
- Lithium Pharmacodynamics and Pharmacogenetics: Focus on Inositol Mono Phosphatase (IMPase), Inositol Poliphosphatase (IPPase) and Glycogen Sinthase Kinase 3 Beta (GSK-3 Beta)
- (2009) Alessandro Serretti et al. CURRENT MEDICINAL CHEMISTRY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- High grade osteosarcoma of the extremities metastatic to the lung: Long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005
- (2009) Antonio Briccoli et al. SURGICAL ONCOLOGY-OXFORD
- Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients
- (2008) Stefan S. Bielack et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now